Dupilumab for Asthma

Phase-Based Progress Estimates
3
Effectiveness
3
Safety
Asthma
Dupilumab - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test whether the drug dupilumab can improve mucus clearance in asthma patients.

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Other trials for Asthma

Study Objectives

1 Primary · 6 Secondary · Reporting Duration: Measured from baseline to 12 weeks after start of treatment

Week 12
Change in mucociliary clearance (MCC) rate
Week 12
Change in ACT score
Change in FEV1% predicted
Change in mucus plugging score by CT
Change in sputum eosinophils and T2 gene mean
Peripheral and central lung MCC90, MCC240, AAC90
Whole lung MCC90, AAC90

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Other trials for Asthma

Trial Design

2 Treatment Groups

Dupilumab
1 of 2
Placebo
1 of 2
Active Control
Non-Treatment Group

30 Total Participants · 2 Treatment Groups

Primary Treatment: Dupilumab · Has Placebo Group · Phase 4

Dupilumab
Drug
ActiveComparator Group · 1 Intervention: Dupilumab · Intervention Types: Drug
Placebo
Other
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Other

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: measured from baseline to 12 weeks after start of treatment

Who is running the clinical trial?

Sally E. Wenzel MDLead Sponsor
4 Previous Clinical Trials
765 Total Patients Enrolled
4 Trials studying Asthma
765 Patients Enrolled for Asthma

Eligibility Criteria

Age 18+ · All Participants · 8 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
, OR on a leukotriene modifier Asthma that is moderate to severe and requires treatment with high doses of inhaled corticosteroids (ICS) to control symptoms, OR treatment with a leukotriene modifier.
If your forced vital capacity (FVC) is less than 75%, then this means that your FEV1 is also below the normal range.
An asthma control test (ACT) score of less than 20 suggests that your asthma is not well controlled.
The text states that if a person has a reversible airflow limitation that is less than 12% at screening or within the past 2 years, or if they have a positive methacholine challenge test within the past 2 years, or if they have a positive methacholine challenge during screening, then they are not eligible to participate in the study.
: A blood test shows that the number of eosinophils in your blood is more than 300 cells per mm3.
for up to one year were not associated with an increased risk of bone loss Inhaled steroid doses of 500mcg or more per day for up to one year were not associated with an increased risk of bone loss.
is associated with asthma If someone's FeNO level is >25 parts per billion, it is associated with asthma.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 26th, 2021

Last Reviewed: October 29th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.